Redhill Biopharma Ltd
Research Redhill Biopharma Ltd (RDHL) on Bullrun: market cap USD 2.80M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRDHL
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 2.80M
- Financial periodFY2025
- RevenueUSD 286.00K
- Net income-USD 429.00K
- Free cash flow-USD 9.66M
Valuation Snapshot
latest market cap is USD 2.80M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 286.00K | -USD 429.00K | -USD 9.66M | n/a | n/a | USD 3.97M | USD 1.07M | USD 4.27M |
| FY2024 | USD 0 | -USD 8.27M | -USD 9.38M | n/a | 0 | USD 4.62M | USD 356.00K | -USD 4.68M |
| FY2023 | USD 0 | USD 23.92M | -USD 35.83M | n/a | 100 | USD 5.57M | USD 1.17M | USD 2.07M |
| FY2022 | USD 61.80M | -USD 71.67M | -USD 29.38M | 46.1% | -1200 | USD 19.97M | USD 122.69M | -USD 48.40M |
| FY2021 | USD 85.76M | -USD 97.74M | -USD 65.16M | 42.4% | -2100 | USD 29.47M | USD 87.81M | USD 8.88M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 2.80M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.25M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.01M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 28.73M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.77M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 135.19M | n/a | n/a | n/a |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Redhill Biopharma Ltd's market cap?
Redhill Biopharma Ltd's market capitalization is USD 2.80M.
What does Redhill Biopharma Ltd do?
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.